Table 2 Pharmacokinetics of intravenous ITPP administration per cohort.

From: Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

Cohort (Single dose)

Cmin [mg/L]

Cmax [mg/L]

Tmax [h]

Clast [mg/L]

Tlast [h]

Half life/T0.5 [h]

Elimination rate λz [/h]

AUC [h*mg/L]

AUMC [h2*mg/L]

MRT [h]

CL [L/h]

VSS [L]

1 (1866 mg/m2)

0.0

47.2

6.0

19.2

10.0

1.3

0.5

350.7

1994.7

1.7

4.8

11.0

2 (3732 mg/m2)

0.0

120.6

6.0

55.8

10.0

1.8

0.4

847.4

4925.6

1.8

3.8

10.5

3 (5600 mg/m2)

0.0

153.4

6.0

59.5

10.0

1.4

0.5

1168.7

6445.9

1.5

4.4

9.2

4 (7000 mg/m2)

0.0

228.0

6.0

127.5

10.0

3.3

0.2

1649.5

9421.8

1.7

3.1

12.8

5 (8750 mg/m2)

0.0

257.8

6.0

116.8

10.0

2.1

0.3

1850.5

10396.4

1.6

4.0

11.1

6 (10500 mg/m2)

0.0

313.4

6.0

186.4

10.0

2.6

0.3

2439.2

13886.7

1.7

3.3

11.7

7 (12390 mg/m2)

0.0

353.6

6.0

149.4

10.0

1.7

0.4

2457.2

14095.2

1.7

4.4

11.4

8 (14500 mg/m2)

0.0

439.2

6.0

166.0

10.0

1.8

0.4

2864.1

16280.4

1.7

4.4

11.4

  1. Cmin [mg/L] = minimal concentration at start of infusion; Cmax [mg/L] = maximum concentration; Tmax [h] = time of maximum concentration; Clast [mg/L] = last positive concentration observed; Tlast [h] = time of last positive concentration; Half-life / T0.5 [h] = half-life by lambda z = ln(2)/λz; Elimination rate λz [/h] = lambda z, negative of best fit terminal slope; AUC [h*mg/L] = Area under the curve from 0 to Tlast; AUMC [h2*mg/L] = Area under the first moment curve to the Tlast; MRT [h] = mean residence time; CL [L/h] = clearance; VSS [L] = volume of distribution at steady state
Back to article page